Date: 01-Nov-2019

FDA approves Biogen and Alkermes' multiple sclerosis drug

The U.S. Food and Drug Administration approved Biogen Inc and partner Alkermes Plc's oral drug to treat multiple sclerosis, the companies said on Wednesday. The approval is good news for Biogen as its top-selling drug Tecfidera, also a multiple sclerosis treatment, is facing patent challenges and increased competition from newer treatments such as Roche AG's Ocrevus. The new drug, Vumerity, was approved to treat relapsing forms of multiple sclerosis, a disabling autoimmune disease that damages the central nervous system and can lead to fatigue, pain, vision loss and impaired coordination and motor skills.